Analyst Price Target is $16.50
▲ +109.39% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ESSA Pharma in the last 3 months. The average price target is $16.50, with a high forecast of $17.00 and a low forecast of $16.00. The average price target represents a 109.39% upside from the last price of $7.88.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in ESSA Pharma. This Buy consensus rating has held steady for over two years.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.